Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Femasys Inc (NQ: FEMY )

1.280 +0.040 (+3.22%)
Streaming Delayed Price Updated: 3:23 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 306,965
Open 1.240
Bid (Size) 1.260 (25)
Ask (Size) 1.280 (8)
Prev. Close 1.240
Today's Range 1.210 - 1.330
52wk Range 0.2479 - 4.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
Lee-Sepsick Discussed Company’s FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis 
From Femasys Inc.
Via GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
Lee-Sepsick Discussed Atlanta-Based Biomedical Company’s Women’s Reproductive Health Products 
From Femasys Inc.
Via GlobeNewswire

Performance

YTD
+26.72%
+26.72%
1 Month
-3.77%
-3.77%
3 Month
-12.34%
-12.34%
6 Month
+24.26%
+24.26%
1 Year
+70.65%
+70.65%

More News

Read More
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
From Femasys Inc.
Via GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
From Femasys Inc.
Via GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
From Femasys Inc.
Via GlobeNewswire
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
From Femasys Inc.
Via GlobeNewswire
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
From Femasys Inc.
Via GlobeNewswire
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
From Femasys Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
From Femasys Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.